ArticleNeurochemical research2020
Mulberry Fruit Extract Alleviates Cognitive Impairment by Promoting the Clearance of Amyloid-β and Inhibiting Neuroinflammation in Alzheimer's Disease Mice.
Article in Neurochemical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Effect ofLife (Basel, Switzerland) · 2026Article
- Mulberry Leaf Extracts and Neochlorogenic Acid Ameliorated Scopolamine-induced Cognitive Dysfunction through Promotion of Adult Hippocampal Neurogenesis.International journal of medical sciences · 2026Article
- Pharmacological Characterization ofRecent advances in inflammation & allergy drug discovery · 2026Article
- HPLC/UV analysis of mulberry vinegar and its protective role in LPS-induced cognitive impairment via regulating NF-κB signaling pathway and amyloidogenesis in mice.Food science and biotechnology · 2025Article
- Research Progress on Phytochemicals from Mulberry with Neuroprotective Effects: A Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- IL-17 A Exacerbated Neuroinflammatory and Neurodegenerative Biomarkers in Intranasal Amyloid-Beta Model of Alzheimer's Disease.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Plant-Based Inhibitors of Protein Aggregation.Biomolecules · 2025Review
- Edible Berries- An Update on Nutritional Composition and Health Benefits- Part III.Current nutrition reports · 2025Review
- Advancements in multi-omics research to address challenges in Alzheimer's disease: a systems biology approach utilizing molecular biomarkers and innovative strategies.Frontiers in aging neuroscience · 2025Review
- Flavonoids as Potential Therapeutics Against Neurodegenerative Disorders: Unlocking the Prospects.Neurochemical research · 2024Review
- Secondary Bioactive Metabolites from Foods of Plant Origin asFoods (Basel, Switzerland) · 2024Review
- Contribution of Extracellular Particles Isolated fromInternational journal of molecular sciences · 2024Article
- Gut Microbiota and its Metabolites: Bridge of Dietary Nutrients and Alzheimer's Disease.Advances in nutrition (Bethesda, Md.) · 2023Review
- Gossypetin- based therapeutics for cognitive dysfunction in chronic unpredictable stress- exposed mice.Metabolic brain disease · 2022Article
- Phytochemicals, Pharmacological Effects and Molecular Mechanisms of Mulberry.Foods (Basel, Switzerland) · 2022Review
- Avicularin Attenuates Memory Impairment in Rats with Amyloid Beta-Induced Alzheimer's Disease.Neurotoxicity research · 2022Article
- Pharmacological Activities forFoods (Basel, Switzerland) · 2021Review
- Review
- Neuroprotective Effects of Withania somnifera on 4-Hydroxynonenal Induced Cell Death in Human Neuroblastoma SH-SY5Y Cells Through ROS Inhibition and Apoptotic Mitochondrial Pathway.Neurochemical research · 2021Article
- Myricetin as a Promising Molecule for the Treatment of Post-Ischemic Brain Neurodegeneration.Nutrients · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a common neurodegenerative disease, always clinically manifesting with memory loss and other cognitive abilities serious enough to interfere with daily life. Over the past decade, the extensive accumulation of Aβ plaques and the related neuroinflammation such as the activation of glial cells have been frequently demonstrated to contribute to the pathogenesis of AD. However, drugs promoting Aβ plaques degradation and modulating the neuroinflammation remain undeveloped for AD treatment. Mulberry (or Morus alba Linn.) fruit, a common folk medicine, has been demonstrated to exhibit a considerable neuroprotective effect such as promoting memory impairment and enhancing cognitive ability on Parkinson's-disease-related animal models. Whether mulberry fruit can treat or alleviate AD-related symptoms are unclear so far. In the present study, we estimated the neuroprotective effects of mulberry fruit ethanol extract (MFE) using APP/PS1 transgenic mice, a widely used AD animal model. We found that daily oral MFE (100 mg/kg body weight, for 1.5-3 weeks) remarkably improved the spatial memory and learning ability of APP/PS1 mice, determined by behavioral tests including the Rotarod, Elevated plus maze and Morris water maze test. In histological, we observed that MFE reduced Aβ plaques and neuron apoptosis both in the cortex and hippocampus tissues of APP/PS1 mice. Moreover, MFE treatment noticeably alleviated the neuroinflammation, indicated by the decreased number of astrocytes in the cortex and hippocampus of APP/PS1 mice. These results were further confirmed by the elevation of anti-inflammatory cytokines (IL-4) and reduction of pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) in the cortex and hippocampus tissues of MFE-treated APP/PS1 mice. Collectively, our findings demonstrate that MFE exhibits a good neuroprotective effect on APP/PS1 mice. Therefore, MFE may be a promising therapeutic drug in the treatment of neurodegenerative disorders, especially like AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.